Aloke Dutta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12184183/publications.pdf

Version: 2024-02-01

	1307594	1588992	
162	7	8	
citations	h-index	g-index	
8	8	263	
docs citations	times ranked	citing authors	
	citations 8	162 7 citations h-index 8 8	

#	Article	IF	CITATIONS
1	A Rare Case of SARS-CoV-2 Infection Associated With Pituitary Apoplexy Without Comorbidities. Journal of the Endocrine Society, 2021, 5, bvaa203.	0.2	29
2	Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?. Future Medicinal Chemistry, 2015, 7, 2385-2406.	2.3	35
3	Development of potent dopamine–norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template. Bioorganic and Medicinal Chemistry, 2015, 23, 821-828.	3.0	6
4	Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model. Bioorganic and Medicinal Chemistry, 2014, 22, 311-324.	3.0	14
5	Structural Modifications of Neuroprotective Anti-Parkinsonian (â^')- <i>N</i> 6-(2-(4-(Biphenyl-4-yl)piperazin-1-yl)-ethyl)- <i>N</i> 6-propyl-4,5,6,7-tetrahydrobenzo[<i>d</i>]thia: (D-264): An Effort toward the Improvement of in Vivo Efficacy of the Parent Molecule. Journal of Medicinal Chemistry, 2014, 57, 1557-1572.	zolę-2,6-dia	amjnge
6	D-512 and D-440 as Novel Multifunctional Dopamine Agonists: Characterization of Neuroprotection Properties and Evaluation of In Vivo Efficacy in a Parkinson's Disease Animal Model. ACS Chemical Neuroscience, 2013, 4, 1382-1392.	3.5	25
7	Further Structureâ^'Activity Relationship Studies on 4-((((3S,6S)-6-Benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Identification of Compounds with Triple Uptake Inhibitory Activity as Potential Antidepressant Agents. Journal of Medicinal Chemistry, 2011, 54, 2924-2932.	6.4	16
8	An improved asymmetric synthetic route to a novel triple uptake inhibitor antidepressant (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol (D-142). Tetrahedron: Asymmetry, 2011, 22, 1081-1086.	1.8	9